-
President Joe Biden is campaigning on his efforts to cut drug costs for Medicare patients. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
-
Independent pharmacists say they're losing money on many prescriptions they fill. “It’s just a lot of different elements in the system all at once," says a pharmacy assistant professor at FAMU.
-
A study by the Rand Corp., a nonpartisan research organization, found that, across all drugs, U.S. prices were 2.78 times higher than the prices in 33 OECD countries. The gap was even larger for brand-name drugs.
-
Drugmakers offer copay assistance programs to patients, but insurers are tapping into those funds, not counting the amounts toward patient deductibles. That leads to unexpected charges. But the practice is under growing scrutiny.
-
The presidential election is likely to turn on the simple question of whether Americans want Donald Trump back in the White House. But health care tops the list of household financial worries for adults from both parties.
-
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
-
It’s a big job clearing out so-called “patent thickets” drugmakers create to keep their products’ prices high. But the Federal Trade Commission is giving it a shot.
-
It's our monthly medical roundtable, when we dive into the month's most significant health headlines.
-
HHS issued a summary about a Jan. 12 discussion between Secretary of Health Xavier Becerra and Canadian Health Minister Mark Holland.
-
Florida Hospital Association president Mary Mayhew tells "The Florida Roundup" that she hopes people can start benefitting from the program within the year.